Related Experiment Videos
Hyperlipidemia after organ transplantation
1Department of Medicine, SUNY Health Science Center, Brooklyn 11203.
The American Journal of Medicine
|November 1, 1989
Summary
Post-transplant hyperlipidemia is a common complication, potentially causing accelerated atherosclerosis and graft loss. Different immunosuppressants like cyclosporine can lead to distinct lipid profiles, requiring careful management.
Area of Science:
- Nephrology
- Cardiology
- Immunology
Background:
- Hyperlipidemia is a frequent and challenging issue after organ transplantation.
- It may underlie accelerated atherosclerosis in heart transplant recipients and renal transplant patients.
- Hyperlipidemia might also contribute to long-term renal graft loss.
Purpose of the Study:
- To explore the causes and implications of hyperlipidemia in organ transplant recipients.
- To differentiate lipid abnormalities associated with specific immunosuppressive agents.
- To discuss initial therapeutic strategies for post-transplant hyperlipidemia.
Main Methods:
- Review of existing literature on post-transplant hyperlipidemia.
- Analysis of lipid profiles in patients treated with azathioprine/prednisone versus cyclosporine.
- Discussion of the potential mechanisms of hyperlipidemia induced by immunosuppressants.
Main Results:
- Hypertriglyceridemia is common with azathioprine and prednisone, linked to calorie intake and glucose intolerance.
- Hypercholesterolemia is more frequent with cyclosporine, potentially due to LDL receptor interference.
- Cyclosporine may also impact bile acid synthesis and glucose tolerance, exacerbating hyperlipidemia.
Conclusions:
- Post-transplant hyperlipidemia has varied causes depending on immunosuppressive therapy.
- Dietary modifications (calorie-fat restriction, fiber) are initial management steps.
- Pharmacologic lipid-lowering agents require cautious use and further study in transplant patients.